Tagraxofusp

Sharing is caring!

What is Tagraxofusp

Tagraxofusp-erzs is a CD123-directed cytotoxin that is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm in adult and pediatric patients 2 years of age and older.

Capillary leak syndrome has been reported with tagraxofusp therapy

Brand Name

ELZONRIS

Indications

  • blastic plasmacytoid dendritic cell neoplasm

Side Effects

  1. anemia
  2. anorexia
  3. antibody formation
  4. anxiety
  5. back pain
  6. bradycardia
  7. capillary leak syndrome
  8. chills
  9. confusion
  10. constipation
  11. cough
  12. diarrhea
  13. dizziness
  14. dyspnea
  15. edema
  16. elevated hepatic enzymes
  17. epistaxis
  18. fatigue
  19. fever
  20. headache
  21. hematuria
  22. hyperbilirubinemia
  23. hyperglycemia
  24. hyperkalemia
  25. hypermagnesemia
  26. hypernatremia
  27. hypertension
  28. hypoalbuminemia
  29. hypocalcemia
  30. hypoglycemia
  31. hypokalemia
  32. hypomagnesemia
  33. hyponatremia
  34. hypophosphatemia
  35. hypotension
  36. insomnia
  37. nausea
  38. neutropenia
  39. peripheral edema
  40. petechiae
  41. pruritus
  42. rash
  43. sinus tachycardia
  44. stomatitis
  45. thrombocytopenia
  46. vomiting
  47. weight gain
  48. wheezing

Monitoring Parameters

  • blood pressure
  • heart rate
  • LFTs
  • pregnancy testing
  • serum albumin
  • serum creatinine
  • weight

Contraindications

  • breast-feeding
  • capillary leak syndrome
  • contraception requirements
  • geriatric
  • hepatic disease
  • pregnancy
  • pregnancy testing
  • renal impairment
  • reproductive risk
  • serious rash

Interactions

  • Palifermin
  • Penicillamine
  • Tuberculin Purified Protein Derivative, PPD

Sharing is caring!

15585

Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

15856
Scroll to Top